Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, Ferguson M, Hillemanns P, McNeil SA, Peters K, Ramjattan B, Schwarz TF, Supparatpinyo K, Suryakirian PV, Janssens M, Moris P, Decreux A, Poncelet S, Struyf F.
Folschweiller N, et al. Among authors: supparatpinyo k.
J Infect Dis. 2019 May 5;219(11):1799-1803. doi: 10.1093/infdis/jiy743.
J Infect Dis. 2019.
PMID: 30715452
Free PMC article.
Clinical Trial.